This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2010 Nov 15;68(10):876-8.

doi: 10.1016/j.biopsych.2010.09.020.

What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?

Jeffrey Cummings¹

Affiliations

PMID: 21035622
DOI: 10.1016/j.biopsych.2010.09.020

What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?

Jeffrey Cummings. Biol Psychiatry. 2010.

. 2010 Nov 15;68(10):876-8.

doi: 10.1016/j.biopsych.2010.09.020.

Author

Jeffrey Cummings¹

Affiliation

¹ Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland Clinic Neurological Institute, Las Vegas, Nevada 89106, USA. cumminj@ccf.org

PMID: 21035622
DOI: 10.1016/j.biopsych.2010.09.020

No abstract available

PubMed Disclaimer

Similar articles

What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.
Schor NF. Schor NF. Ann Neurol. 2011 Feb;69(2):237-9. doi: 10.1002/ana.22365. Ann Neurol. 2011. PMID: 21387368
Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer's disease.
Imbimbo BP, Peretto I. Imbimbo BP, et al. Curr Opin Investig Drugs. 2009 Jul;10(7):721-30. Curr Opin Investig Drugs. 2009. PMID: 19579178
A phase 3 trial of semagacestat for treatment of Alzheimer's disease.
Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, Aisen PS; Alzheimer's Disease Cooperative Study Steering Committee; Siemers E, Sethuraman G, Mohs R; Semagacestat Study Group. Doody RS, et al. N Engl J Med. 2013 Jul 25;369(4):341-50. doi: 10.1056/NEJMoa1210951. N Engl J Med. 2013. PMID: 23883379 Clinical Trial.
Learning by failing: ideas and concepts to tackle γ-secretases in Alzheimer's disease and beyond.
De Strooper B, Chávez Gutiérrez L. De Strooper B, et al. Annu Rev Pharmacol Toxicol. 2015;55:419-37. doi: 10.1146/annurev-pharmtox-010814-124309. Epub 2014 Oct 1. Annu Rev Pharmacol Toxicol. 2015. PMID: 25292430 Review.
Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease.
Henley DB, May PC, Dean RA, Siemers ER. Henley DB, et al. Expert Opin Pharmacother. 2009 Jul;10(10):1657-64. doi: 10.1517/14656560903044982. Expert Opin Pharmacother. 2009. PMID: 19527190 Review.

See all similar articles

Cited by

Inhibitors of γ-secretase stabilize the complex and differentially affect processing of amyloid precursor protein and other substrates.
Barthet G, Shioi J, Shao Z, Ren Y, Georgakopoulos A, Robakis NK. Barthet G, et al. FASEB J. 2011 Sep;25(9):2937-46. doi: 10.1096/fj.11-183806. Epub 2011 May 19. FASEB J. 2011. PMID: 21597003 Free PMC article.
Emerging Nanotechnology for the Treatment of Alzheimer's Disease.
Singh A, Ansari VA, Mahmood T, Ahsan F, Wasim R, Maheshwari S, Shariq M, Parveen S, Shamim A. Singh A, et al. CNS Neurol Disord Drug Targets. 2024;23(6):687-696. doi: 10.2174/1871527322666230501232815. CNS Neurol Disord Drug Targets. 2024. PMID: 37138478 Review.
Striking reduction of amyloid plaque burden in an Alzheimer's mouse model after chronic administration of carmustine.
Hayes CD, Dey D, Palavicini JP, Wang H, Patkar KA, Minond D, Nefzi A, Lakshmana MK. Hayes CD, et al. BMC Med. 2013 Mar 26;11:81. doi: 10.1186/1741-7015-11-81. BMC Med. 2013. PMID: 23531149 Free PMC article.
Individual and combined presenilin 1 and 2 knockouts reveal that both have highly overlapping functions in HEK293T cells.
Lessard CB, Rodriguez E, Ladd TB, Minter LM, Osborne BA, Miele L, Golde TE, Ran Y. Lessard CB, et al. J Biol Chem. 2019 Jul 19;294(29):11276-11285. doi: 10.1074/jbc.RA119.008041. Epub 2019 Jun 5. J Biol Chem. 2019. PMID: 31167792 Free PMC article.
Alzheimer's disease clinical trials: changing the paradigm.
Cummings JL. Cummings JL. Curr Psychiatry Rep. 2011 Dec;13(6):437-42. doi: 10.1007/s11920-011-0234-y. Curr Psychiatry Rep. 2011. PMID: 22052382 No abstract available.

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information